Featured Article
Scientists have identified a biomarker for Crohn´s disease that also participates in its pathogenesis and occurs years before the disease shows its full clinical spectrum.
Precision Oncology Today
Magazine
MRD: The Future Foundation of Solid Tumor Trials
The terms minimal residual disease, measurable residual disease, and molecular residual disease, interchangeably referred to as MRD, denote what is left after cancer treatment with curative intent. Originally used to monitor patients with hematologic malignancies, MRD is becoming increasingly important in the field of solid tumor oncology because of its correlation with disease outcomes.
Relatively Speaking: Unexpected Detours, Can Inconclusive Prenatal Genetic Tests Save Lives?
Uncertain genetic testing results are not an unusual event in the field of genetic counseling. Obstetricians routinely refer patients to genetic counselors to help them navigate unclear prenatal genetic testing results by reviewing the complexities of genetic information and discussing the benefits, risks, and limitations of additional testing.
Trending on Inside Precision Medicine
People At High Genetic Risk for Dementia Also Benefit from Lifestyle Changes
People in the highest category of genetic risk for dementia can reduce risks by making seven beneficial lifestyle changes, say researchers.
FDA Grants Seribantumab Fast Track Designation for Tumors with NRG1 Gene Fusions
Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3).
Blood Biomarker Predicts Severe Crohn’s Disease Years Before Diagnosis
Scientists have identified a biomarker for Crohn´s disease that also participates in its pathogenesis and occurs years before the disease shows its full clinical spectrum.
